Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

Phase 2

Withdrawn

• Conditions: Breast Cancer
• Interventions: Drug: PF-03084014; Procedure: Breast cancer surgery

• Registration Number: NCT02338531
• Lead Sponsor: Jules Bordet Institute

Brief Summary

This is a phase II open label Biomarker Research Study off PF-03084014 in non-metastatic triple-negative breast cancer patients with residual disease (cHEmoresistant) after completion of standard neoadjuvant chemotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-01-05
• Study First Submitted QC: 2015-01-09
• Study First Posted: 2015-01-14
• Study Start: 2015-06
• Status Verified: 2016-04
• Last Update Submitted: 2016-04-28
• Last Update Posted: 2016-04-29
• Primary Completion: 2018-09
• Study Completion: 2018-12

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

1. Age ≥18 years old.

2. Female.

3. Histological diagnosis of triple-negative breast cancer (TNBC) breast adenocarcinoma (ER<1%, PR<1% by (IHC) and HER-2 0-1+ by IHC or IHC 2+ and FISH or CISH negative per updated ASCO guidelines).

4. No clinical or radiologic evidence of distant metastasis.

5. Presence of residual primary disease of at least 1.5 cm by U/S or MRI within 14 days preceding the last cycle of standard anthracycline and taxane-based neoadjuvant chemotherapy.

   Patients with synchronous synchronous bilateral cancer and unilateral multifocal or multicentric or bilateral disease breast cancer will be allowed provided histologic diagnosis of TNBC is found on all performed biopsies.

6. Completion of standard anthracycline and taxane-based neoadjuvant chemotherapy. The use of platinum agents in combination with standard neoadjuvant chemotherapy is allowed.

7. ECOG Performance Status (PS) 0 or 1

8. Adequate Bone Marrow Function: Absolute Neutrophil Count (ANC) ≥ 1500/μL or ≥1.5 x 109/L; Platelets ≥100000/μL or ≥100 x 109/L; Hemoglobin ≥ 9 g/dL.

9. Adequate Renal Function: Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or estimated creatinine clearance ≥ 60 ml/min.

10. Adequate Liver Function:Total serum bilirubin ≤ 1.0 x ULN or ≤ 2 x ULN in cases of known Gilberts syndrome; Aspartate and Alanine Aminotransferase (AST and ALT) ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN.

11. For patients of childbearing potential: negative serum/urine pregnancy test and use accepted forms of non-hormonal contraception during the study period and up to 6 months after treatment completion.

Exclusion Criteria

1. Concurrent anti-cancer therapy for current breast cancer (hormone therapy, chemotherapy, radiotherapy, immunotherapy). Patients already included in another therapeutic trial involving an experimental drug.
2. Pregnant or lactating women.
3. Any prior history of invasive breast cancer.
4. Any previous history of non-breast malignancies (excepted basal cell carcinoma or squamous cell carcinoma of the skin) in the preceding 5 years.
5. Known hypersensitivity to the study drug or excipients.
6. Patients with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study.
7. Subjects unable to swallow oral medications.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Therapeutic regimen	PF-03084014	oral administration of PF-03084014, 9 days at 150 mg q.d. (day 1 and 9) and 150 b.i.d. (day 2 till 8)
Therapeutic regimen	Breast cancer surgery	oral administration of PF-03084014, 9 days at 150 mg q.d. (day 1 and 9) and 150 b.i.d. (day 2 till 8)

Primary Outcome Measures

Name	Time	Method
HES4 gene expression level	tumour tissue samples before study drug and after 9 days of study drug. General analysis after all patients included.	To demonstrate that PF-03084014 is able to modulate the Notch pathway by down-regulating the expression of the tumor HES4 gene in chemoresistant TNBC (evaluable population).

Secondary Outcome Measures

Name	Time	Method
Safety: General assesment of number and grade of adverse events after short(9-day) administration of oral PF-03084014 in patients with chemoresistant TNBC.	adverse events followed up to 28 days after last PF-03084014 dose.	Patients will be followed for Adverse Events and Serious Adverse Events from the first dose of study drug up to 28 days after the last dose.
Transcriptome analysis (changes in the HES4 gene expression and tumor transcriptome)	tissue samples before study drug and after 9 days of study drug. General analysis after all patients included.	To assess changes in the HES4 gene expression and tumor transcriptome for all patients registered in the RHEA study (intent-to-treat population)

Trial Locations

Locations (5)

Institut Jules Bordet; 🇧🇪 Brussels, Belgium

Institut Curie; 🇫🇷 Paris, France

CMSE; 🇧🇪 Namur, Belgium

Institut de Cancérologie Gustave Roussy; 🇫🇷 Villejuif, France

Grand Hopital de Charleroi; 🇧🇪 Charleroi, Belgium